Hematology Disease Topics & Pathways:
Research, Biological therapies, clinical trials, adult, Translational Research, epidemiology, Plasma Cell Disorders, Combination therapy, Clinical Research, Checkpoint Inhibitor, Diseases, immune mechanism, Therapies, Lymphoid Malignancies, metabolism, Biological Processes, microbiome, Metabolic Disorders, Study Population, Human
Epidemiologic studies have shown associations between unhealthy dietary patterns and the risk of hematologic malignancies although mechanistic data are sparse. With recent advances in methods to study metabolism, microbiome, and the immune system, it is possible to gain a deeper mechanistic understanding into dietary effects. Currently, there are a limited number of dietary intervention trials in hematologic malignancies and their precursor disorders, although interest is growing.
This session will focus on mechanistic insights and biomarker strategies that aide in nutrition in blood cancer research. We will discuss metabolic, microbiome, and immune mechanisms by which diet may affect/modulate hematologic malignancies.
Dr. Catherine Marinac will review the epidemiological evidence linking dietary patterns, metabolic disease (such as obesity and diabetes), and hematologic malignancies. Additional metabolic biomarkers such as markers of insulin resistance and its association with hematologic malignancies will be discussed. She will discuss ongoing and future strategies to translate epidemiological findings to interventional trials in the clinic.
Dr. Matteo Bellone will discuss the evidence linking diet, microbiome, and hematologic malignancies. The gut microbiome composition modulates the host immune response (innate and adaptive) and eventually impacts tumor growth. There will be special emphasis on dietary patterns (such as plant based high fiber diets and western high fat and protein diets) that affect the gut microbiome composition (specifically species and genus). This will be discussed in the context of translational studies with myeloma mouse models. The gut microbiome or its related metabolites may also be manipulated to improve the efficacy of checkpoint blockers.
Dr. Urvi Shah will present the evidence linking diet, the immune system, and hematologic malignancies (with a special focus on plasma cell disorders). The talk will discuss the potential impact of dietary patterns on the immune microenvironment and the immune system and thus disease course. Lastly, the role of dietary interventions in clinical trials studying disease progression, overall response rates, and potential synergy with immunotherapies will also be examined.